Management of renal anaemia: comparison of practice in the Czech Republic and Northern England
Language English Country Belgium Media print
Document type Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
- MeSH
- Anemia blood drug therapy etiology MeSH
- Kidney Failure, Chronic complications MeSH
- Erythropoietin therapeutic use MeSH
- Humans MeSH
- Recombinant Proteins therapeutic use MeSH
- Practice Guidelines as Topic MeSH
- Iron therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Geographicals
- England MeSH
- Czech Republic MeSH
- Names of Substances
- Erythropoietin MeSH
- Recombinant Proteins MeSH
- Iron MeSH
The EDTNA/ERCA European Practice Database (EPD) questionnaire was piloted in the Czech Republic (CZ), Northern Italy and Northern England (N-ENG) in early 2003. The questionnaire used in the CZ and N-ENG featured additional questions on the use of erythropoetin (EPO) and intravenous (IV) iron. There were significant differences in the policies for anaemia management in the CZ and N-ENG, reflecting the higher level of funding available to centres in the UK. There was also a wide variation in practice between the CZ centres, but not those in N-ENG, possibly due to the adoption of guidelines that are currently unrealistic. Some centres, particularly those in the CZ, could improve outcomes or reduce overall costs by adopting a more aggressive policy for the use of intravenous iron.
References provided by Crossref.org
